文献速递产科妇科

产后即刻植入依托孕烯避孕植入物与静脉血栓栓塞症的相关性

Association of Immediate Postpartum Etonogestrel Implant Insertion and Venous Thromboembolism.
PubMed 文献 · Obstet Gynecol · 2020-01-01

基于2016年全国再入院数据库的回顾性队列研究,分析单胎分娩后30天内因静脉血栓栓塞症(VTE)再入院率,比较产后即刻植入依托孕烯避孕植入物与未植入者的差异。结果显示两组VTE再入院率无显著差异(调整后OR 1.81,95%CI 0.44-7.45),但样本量不足以确定无差异。

要点

  • 产后即刻植入依托孕烯避孕植入物未显著增加30天内VTE再入院率。
  • 暴露组VTE再入院率为0.85/1000次分娩,非暴露组为0.35/1000次分娩。
  • 研究样本量不足以确定两组间无差异,需更大样本验证。

核心结论

  • 产后即刻植入依托孕烯避孕植入物与VTE再入院率增加无关,但样本量不足以确定无差异。

研究设计与样本

  • 使用2016年全国再入院数据库的回顾性队列研究,纳入单胎分娩妇女,排除既往VTE或抗凝治疗者。
  • 共分析3,387,120次分娩,其中8,369例在分娩住院期间植入依托孕烯避孕植入物。

主要发现

  • 暴露组7例因VTE再入院(0.85/1000次分娩,95%CI 0.22-1.45/1000),非暴露组1,192例(0.35/1000次分娩,95%CI 0.33-0.37/1000),OR 2.41(95%CI 0.58-9.89)。
  • 调整混杂因素后,VTE再入院率仍无差异(调整OR 1.81,95%CI 0.44-7.45)。
  • 暴露组更年轻,且政府保险、吸烟史、高血压、围产期感染或产后出血比例更高(P<.001)。

关键数值与推荐

  • 暴露组VTE再入院率0.85/1000次分娩(95%CI 0.22-1.45/1000),非暴露组0.35/1000次分娩(95%CI 0.33-0.37/1000)。
  • 未调整OR 2.41(95%CI 0.58-9.89),调整后OR 1.81(95%CI 0.44-7.45)。

临床怎么用

  • 产后即刻植入依托孕烯避孕植入物未显示增加VTE再入院风险,可考虑用于产后避孕。
  • 因样本量不足,临床决策需结合个体VTE风险因素综合评估。

局限性

  • 样本量不足以确定两组间无差异(统计效能不足)。
  • 回顾性数据库研究可能存在编码偏倚和混杂因素残余。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the rate of readmissions for postpartum venous thromboembolism (VTE) during the first 30 days postdelivery between women with and without the immediate postpartum insertion of the etonogestrel contraceptive implant. METHODS: The Nationwide Readmissions Database from 2016 was used to identify women with a singleton delivery, immediate postpartum insertion of the etonogestrel contraceptive implant, and readmission for VTE within 30 days of discharge. Those with a prior history of VTE or anticoagulant therapy were excluded. These women were compared with the number of women readmitted within 30 days for VTE who did not have the contraceptive implant placed during delivery admission. RESULTS: Of 3,387,120 deliveries, 8,369 women underwent etonogestrel contraceptive implant placement during the delivery admission. There was no difference identified in the rate of readmission for VTE between exposed and unexposed women. Of these, seven had received a postpartum etonogestrel contraceptive implant (0.85/1,000; 95% CI 0.22-1.45/1,000 deliveries), compared with 1,192 without an etonogestrel contraceptive implant (0.35/1,000; 95% CI 0.33-0.37/1,000 deliveries); odds ratio (OR) 2.41; 95% CI 0.58-9.89. The rates of diabetes, thrombophilia, systemic lupus erythematosus, and cesarean birth did not differ between groups. Women who underwent etonogestrel contraceptive implant placement were younger and were more likely to have government-sponsored health insurance, a smoking history, hypertension, peripartum infection, or postpartum hemorrhage than women who did not receive an etonogestrel contraceptive implant (P<.001). After adjusting for these confounders, there remained no difference in rates of VTE, adjusted OR 1.81; 95% CI 0.44-7.45. CONCLUSION: The immediate postpartum placement of the etonogestrel contraceptive implant was not associated with an increased rate of VTE; however, our sample size was underpowered to determine no difference.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Floyd JL, Beasley AD, Swaim LS, et al. Association of Immediate Postpartum Etonogestrel Implant Insertion and Venous Thromboembolism. Obstet Gynecol. 2020. PMID: 32459418. doi:10.1097/AOG.0000000000003760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。